new glp-1 drugs Guidelines for Type 2 Diabetes in 2025 What to know about the

Severe Side Effects Claimed in Ozempic Lawsuits NAION Blindess Vision Loss Gastroparesis Ileus Intestinal obstruction Intestinal pseudo-obstruction Other gastrointestinal injuries There is no cure for NAION or gastroparesis

Out of 175 different outcomes researchers included in the study, they found people who took GLP-1 medications had lower risks of 42 different health outcomes and higher risks for 19

December 2025: Ascletis Pharma announced that ASC30, an oral small-molecule GLP-1 receptor agonist, demonstrated 7.7% placebo-adjusted weight loss in a 13-week U.S

Doustdar thinks the program could be an opportunity to regain some of the ground Novo's Wegovy shot has lost to Lilly's Zepbound

Slows gastric emptying Tirzepatide slows down the movement of food, so blood sugar levels are more stable, and you stay full longer